Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Goodyear, Arizona, United States
- Research Site
Washington D.C., District of Columbia, United States
- Research Site
Augusta, Georgia, United States
- Research Site
Marietta, Georgia, United States
- Research Site
Ashland, Kentucky, United States
- Research Site
St Louis, Missouri, United States
- Research Site
Mineola, New York, United States
- Research Site
Huntersville, North Carolina, United States
- Research Site
Spokane, Washington, United States
- Research Site
Tacoma, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 25 Jul 2014
- Primary completion
- 11 Jun 2016
- Completion
- 11 Jun 2016
- Last update posted
- 2 Aug 2019
- Registered enrollment
- 32
- Registry id
- NCT02179671
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.